Image by Aleksandr Khakimullin via Shutterstock.com
Embleema[1], a Delaware company, emerged from stealth and launched the public beta of its HIPAA-compliant, personal health records blockchain after one year of research and development, the company said on Tuesday.
PatientTruth[2] is a decentralized application (DApp) and user interface developed by Embleema to allow stakeholders to interact with Embleema’s healthcare blockchain. But more specifically, it is designed for patients and providers to share medical records.
PatientTruth, Embleema
Through PatientTruth, patients can easily integrate all their medical and wellness data on a secured HIPAA compliant record, share these with healthcare stakeholders, and receive compensation for being involved.
Built on Ethereum, the Embleema platform connects patients, life sciences, and regulators, and intends to solve the challenges associated with collection and safe sharing of real world evidence (RWE).
RWE refers[3] to healthcare information collected from multiple sources outside of typical clinical research settings, including electronic medical records (EMRs), claims and billing data, product and disease registries, and data gathered by personal devices and health applications.
RWE plays an important role in decision-making related to authorization and access to new medicines and reimbursement, and are used in critical fields including understanding real world settings such as treatment populations, patterns of care and the burden of disease; assessing the effectiveness of current therapies; refining or supplementing evidence from conventional trials of new medicines; and providing new evidence of relative effectiveness of new medicines.
But current RWE researches suffer from major deficiencies including low-resolution aggregated data sets sold by third party data brokers, the incapacity to secure individual consent, and the inability to monitor the same patient over extended periods of time.
Embleema has set out to solve these issues by allowing patients to consent to real-time data sharing with pharmaceutical companies
